CoChat

Phase 0 Clinical Trials: Conceptions and Misconceptions

Open access
Kummar, Shivaani, Rubinstein, Larry, Kinders, Robert, Parchment, Ralph E., Gutierrez, Martin E., Murgo, Anthony J., Ji, Jay, Mroczkowski, Barbara, Pickeral, Oxana K., Simpson, Mel, Hollingshead, Melinda, Yang, Sherry X., Helman, Lee, Wiltrout, Robert, Collins, Jerry, Tomaszewski, Joseph E., Doroshow, James H. · 2008 · The Cancer Journal
Cited by 110

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Phase 0 clinical trials, developed in response to the United States Food and Drug Administration (FDA)'s recent exploratory Investigational New Drug (IND) guidance, are intended to expedite the clinical evaluation of new molecular entities. The exploratory IND supports the performance of first-in-human testing of new investigational agents at subtherapeutic doses based on reduced manufacturing and toxicologic requirements, allowing the demonstration of drug-target effects and assessment of pharmacokinetic-pharmacodynamic relationships in humans earlier in clinical development. The objectives of a phase 0 cancer clinical trial are to establish at the very earliest opportunity-before large numbers of patients have been accrued and exposed to potential drug-associated toxicity-whether an agent is modulating its target in a tumor, and consequently whether further clinical development is warranted. We review here the fundamental requirements of clinical studies conducted under an exploratory IND and address some common misconceptions regarding oncologic phase 0 trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ppo.0b013e318172d6f3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Can the pharmaceutical industry reduce attrition rates?

    Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×

    “The FDAs exploratory IND guidance provides 3 general examples of early-phase clinical trials that address (1) PK or imaging, (2) pharmacologically relevant doses, and (3) evaluation of an agent’s mechanism of action.”
    Background

Show all 1 references

Cited by

Metadata

Authors
Kummar, S., Rubinstein, L., Kinders, R., Parchment, R. E., Gutierrez, M. E., Murgo, A. J., Ji, J., Mroczkowski, B., Pickeral, O. K., Simpson, M., Hollingshead, M., Yang, S. X., Helman, L., Wiltrout, R., Collins, J., Tomaszewski, J. E., & Doroshow, J. H.
Venue
The Cancer Journal
Published
2008-05
Volume
14
Issue
3
Pages
133-137
ISSN
1528-9117 (ISSN-L)
OpenAlex
W2079914493
Cited by
110
References
1
FWCI
4.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.